Therapy of Dry Eye Syndrome after Inflammatory Diseases of Cornea

Purpose: evaluation of the efficacy of the drug Tealose® in the therapy of cornea inflammatory diseases consequences such as dry eye syndrome.Patients and methods: 34 patients (34 eyes) with dry eye syndrome after inflammatory diseases of the cornea, aged 28–56 years old were included in the study....

Full description

Bibliographic Details
Main Authors: I. A. Gndoyan, A. V. Petrayevsky
Format: Article
Language:Russian
Published: Ophthalmology Publishing Group 2020-04-01
Series:Oftalʹmologiâ
Subjects:
Online Access:https://www.ophthalmojournal.com/opht/article/view/1144
id doaj-b3732747691345349b10947b8d2b1fad
record_format Article
spelling doaj-b3732747691345349b10947b8d2b1fad2021-07-29T08:55:28ZrusOphthalmology Publishing GroupOftalʹmologiâ 1816-50952020-04-0117112413210.18008/1816-5095-2020-1-124-132611Therapy of Dry Eye Syndrome after Inflammatory Diseases of CorneaI. A. Gndoyan0A. V. Petrayevsky1Volgograd State Medical UniversityVolgograd State Medical UniversityPurpose: evaluation of the efficacy of the drug Tealose® in the therapy of cornea inflammatory diseases consequences such as dry eye syndrome.Patients and methods: 34 patients (34 eyes) with dry eye syndrome after inflammatory diseases of the cornea, aged 28–56 years old were included in the study. Two clinical groups were formed: observation group — 20 subjects (20 eye) and comparison group — 14 subjects (14 eyes). The dynamics of such indicators were estimated under therapy: visual acuity with maximal correction, corneal epithelium entity according fluoresceine dye test, tear production according Schirmer and Norn tests, the grade of dry eye syndrome severity according index of OSDI — Questionnarie. The patients in observation group in addition to the basic therapy, which included instillation antiseptics и 4 % taurine solution, were treated with 3 % solution of tregalose (Tealose®, “Laboratuar Thea”, France) by such mode: using of 4 times daily instillations during 1 month, 1 month break, than continuation of the same regimen instillations during 1 month was performed. The patients in comparison group in addition to the same basic therapy were treated with Visomitin® (“Mitotech”, Russia) by the mode, which was used for tregalose.Results. The improvement of cornea’s epithelization (p < 0,05), increasing of visual acuity with maximal correction (p < 0,05), improvement of tear production (p < 0,05), as well as the OSDI-index (p < 0,05) were revealed in the patients of the observation group. In the patients of the comparison group positive dynamics of these indicators was insignificant and unreliable.Conclusions. Using of 3 % tregalose solution in patients with consequences of inflammatory diseases of the cornea — keratitis leads to effective treatment of “dry eye” syndrome, reduces the severity of epithelization disorders and tendency to scarring in the corneal tissue.https://www.ophthalmojournal.com/opht/article/view/1144keratitisconsequencesdry eye syndromevisual acuitycorneal epithelium entityschirmer testnorn testosdi for citation: gndoyan i.a.petrayevsky a.v. therapy of dry eye syndrome after inflammatory diseases of cornea. ophthalmology
collection DOAJ
language Russian
format Article
sources DOAJ
author I. A. Gndoyan
A. V. Petrayevsky
spellingShingle I. A. Gndoyan
A. V. Petrayevsky
Therapy of Dry Eye Syndrome after Inflammatory Diseases of Cornea
Oftalʹmologiâ
keratitis
consequences
dry eye syndrome
visual acuity
corneal epithelium entity
schirmer test
norn test
osdi for citation: gndoyan i.a.
petrayevsky a.v. therapy of dry eye syndrome after inflammatory diseases of cornea. ophthalmology
author_facet I. A. Gndoyan
A. V. Petrayevsky
author_sort I. A. Gndoyan
title Therapy of Dry Eye Syndrome after Inflammatory Diseases of Cornea
title_short Therapy of Dry Eye Syndrome after Inflammatory Diseases of Cornea
title_full Therapy of Dry Eye Syndrome after Inflammatory Diseases of Cornea
title_fullStr Therapy of Dry Eye Syndrome after Inflammatory Diseases of Cornea
title_full_unstemmed Therapy of Dry Eye Syndrome after Inflammatory Diseases of Cornea
title_sort therapy of dry eye syndrome after inflammatory diseases of cornea
publisher Ophthalmology Publishing Group
series Oftalʹmologiâ
issn 1816-5095
publishDate 2020-04-01
description Purpose: evaluation of the efficacy of the drug Tealose® in the therapy of cornea inflammatory diseases consequences such as dry eye syndrome.Patients and methods: 34 patients (34 eyes) with dry eye syndrome after inflammatory diseases of the cornea, aged 28–56 years old were included in the study. Two clinical groups were formed: observation group — 20 subjects (20 eye) and comparison group — 14 subjects (14 eyes). The dynamics of such indicators were estimated under therapy: visual acuity with maximal correction, corneal epithelium entity according fluoresceine dye test, tear production according Schirmer and Norn tests, the grade of dry eye syndrome severity according index of OSDI — Questionnarie. The patients in observation group in addition to the basic therapy, which included instillation antiseptics и 4 % taurine solution, were treated with 3 % solution of tregalose (Tealose®, “Laboratuar Thea”, France) by such mode: using of 4 times daily instillations during 1 month, 1 month break, than continuation of the same regimen instillations during 1 month was performed. The patients in comparison group in addition to the same basic therapy were treated with Visomitin® (“Mitotech”, Russia) by the mode, which was used for tregalose.Results. The improvement of cornea’s epithelization (p < 0,05), increasing of visual acuity with maximal correction (p < 0,05), improvement of tear production (p < 0,05), as well as the OSDI-index (p < 0,05) were revealed in the patients of the observation group. In the patients of the comparison group positive dynamics of these indicators was insignificant and unreliable.Conclusions. Using of 3 % tregalose solution in patients with consequences of inflammatory diseases of the cornea — keratitis leads to effective treatment of “dry eye” syndrome, reduces the severity of epithelization disorders and tendency to scarring in the corneal tissue.
topic keratitis
consequences
dry eye syndrome
visual acuity
corneal epithelium entity
schirmer test
norn test
osdi for citation: gndoyan i.a.
petrayevsky a.v. therapy of dry eye syndrome after inflammatory diseases of cornea. ophthalmology
url https://www.ophthalmojournal.com/opht/article/view/1144
work_keys_str_mv AT iagndoyan therapyofdryeyesyndromeafterinflammatorydiseasesofcornea
AT avpetrayevsky therapyofdryeyesyndromeafterinflammatorydiseasesofcornea
_version_ 1721250970477789184